Heidelberg Epignostix

Heidelberg Epignostix GmbH, operating in the field of molecular diagnostics, was established in 2020 as a spin-off from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital. The company was founded by a team including Prof. Dr. Magnus von Knebel Doeberitz, who has a long-standing research background in molecular biology and tumor research, and Dr. Axel Zucknick. Their research, originating from as early as 2005, focused on DNA methylation changes as biomarkers for the early detection of cancers, particularly cervical cancer.

The core of Heidelberg Epignostix's business revolves around the development and commercialization of novel biomarkers for cancer diagnostics. The company's lead product is a diagnostic test for the early detection of cervical cancer and its precursors. This test identifies specific DNA methylation patterns associated with the disease. The benefit of this approach lies in its potential to provide a more accurate and earlier diagnosis compared to traditional methods. The company leverages a patented biomarker technology platform.

Heidelberg Epignostix operates on a business-to-business model, targeting the in-vitro diagnostics (IVD) market. Its primary clients are diagnostic laboratories and corporations within the life sciences sector. The company's revenue stream is based on licensing its patented biomarker technology and the sale of its diagnostic assays and kits. In a significant milestone, the company entered into a strategic partnership with the diagnostics group Unilabs in 2021 to validate and utilize its cervical cancer screening test.

Keywords: molecular diagnostics, cancer biomarkers, DNA methylation, cervical cancer, early detection, in-vitro diagnostics, life sciences, diagnostic assays, epigenetic biomarkers, medtech